Neurocrine’s Ingrezza Adds Huntington’s Indication, May Have Competitive Edge
Extended-Release Rival Also Approved In 2023
The company’s VMAT2 inhibitor joins others in the drug class with a warning about suicidal ideation, but its once-daily dosing without titration may be an advantage in chorea associated with Huntington’s disease.
